Douglas Miehm
Stock Analyst at RBC Capital
(3.60)
# 789
Out of 5,140 analysts
59
Total ratings
54.55%
Success rate
7.73%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $234 → $235 | $183.98 | +27.73% | 8 | Dec 10, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $17.94 | +5.91% | 14 | Nov 14, 2025 | |
| MNKD MannKind | Maintains: Outperform | $8 → $7.5 | $5.54 | +35.38% | 4 | Nov 11, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $14.40 | +4.17% | 11 | Nov 5, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $6.13 | +63.13% | 21 | May 2, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.96 | +418.67% | 1 | Mar 10, 2025 |
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $234 → $235
Current: $183.98
Upside: +27.73%
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $17.94
Upside: +5.91%
MannKind
Nov 11, 2025
Maintains: Outperform
Price Target: $8 → $7.5
Current: $5.54
Upside: +35.38%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $14.40
Upside: +4.17%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $6.13
Upside: +63.13%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.96
Upside: +418.67%